VRTX"A quick trade for traders based on a classic, well-known pattern: Symmetrical Triangle. Entry at $500, stop loss at $460. First target between $527.5 _ $535. Second target between $544 _ $549." by IbrahimTarek4
VRTX Vertex Pharmaceuticals Options Ahead of EarningsAnalyzing the options chain and the chart patterns of VRTX Vertex Pharmaceuticals prior to the earnings report this week, I would consider purchasing the 472.5usd strike price Puts with an expiration date of 2024-11-8, for a premium of approximately $14.00. If these options prove to be profitable prShortby TopgOptions1
Vertex Pharmaceuticals (VRTX) | Chart & Forecast SummaryRight Here You Can See Vertex Pharmaceuticals Incorporated (VRTX) Registered As (VRTX) On The New York Stock Exchange, Vertex Pharmaceuticals Incorporated Is An American Biopharmaceutical Company Based In Boston, Massachusetts. The Following Chart & Forecast Summary On Vertex Pharmaceuticals IncorpVLong02:05by P-Ment4U0
VRTX Bull FlagVRTX is approaching the top end of bull flag on the 4hr. A break could lead to a move back up to ATH and beyond. The flag pole on this one is pretty big so if going on that projection it could see $600 if it does get continuation above. A bearish scenario would be a rejection here at the top end orLongby AdvancedPlays110
Buy Vertex PharmaceuticalsShort Term Trading Advice by Naranj Capital Buy Vertex Pharmaceuticals ● Buy Range- 475 - 480 ● Target- 500 - 505 ● StopLoss- 460 ● Potential Return- 5-6% ● Duration- 12-14 Trading Days Longby NaranjCapitalUpdated 3
VRTX upside?Beautiful bullflag breaking on the hourly and higher time frames, Targeting previous highsLongby TheBullandBearLounge333
VRTX solid breakoutSolid breakout out of a cup and handle. outperforming overall market. Longby Hawaii2017Updated 11
Eyes on VRTXVRTX bouncing nicely off recent lows and has broken downtrend. Final confirmation would be a daily close over 421.50. Looking to enter a starter position and will add on a retest of the daily 48. Longby Odd_Lot1
Vertex Pharmaceuticals pioneers with non-opioid painkiller VX-54Vertex Pharmaceuticals Inc., widely recognised for its cystic fibrosis treatments, is venturing into new therapeutic areas , signalling potential growth in new markets. The company is currently advancing its development of non-opioid analgesics, specifically candidate VX-548, which has demonstratedby RoboMarkets2
In waiting for a retestAre you interrested in buying NASDAQ:VRTX ? I'm looking for a break confirmation of the 2-years trendline to evaluate a first entry in the 370s. Then the POC line could be a valid support to regain the trend.by alexmerax1